Provera belongs to the class of medicines known asestrogens.This medication is used totreat menstrual disorders in womenand totreat high blood pressure in the blood vessels that carry blood to the brain and spinal cord.Aprogestogenis a synthetic hormone produced by the pituitary gland in the ovaries that stimulates the ovaries to produce more eggs.
This medication is not recommended for use in women with an irregular period.
The dosage of this medication will depend on your specific condition and response to the medicine. Please read the instructions and details below.
The dose of this medication can be increased or decreased depending on the condition being treated and your response to the medicine. A daily dose of 1 tablet is recommended.
If you are pregnant, may become pregnant, or think you may be pregnant, ask your doctor or pharmacist if you should monitor your baby after taking the medication.
If you forget to take a dose of this medication, take it as soon as you remember unless it is almost time for your next dose. In that case, skip the missed dose and resume your usual dosing schedule. Do not take two doses together. Do not take the dose that you missed unless instructed by your doctor.
Side effects may include:
If you experience any side effects, talk to your doctor or pharmacist.
Store this medication at room temperature.
Keep this medication out of the reach and sight of children.
Do not exceed the recommended dose or use this medication for longer than recommended by your doctor.
Do not take the following medications if:
Store at room temperature.
Do not freeze or refrigerate the medication.
Depo-SubQ Provera 104 needs to be given by subcutaneous (hypodermic) injection once every 12 weeks. This is not an intramuscular injection and must be given by someone trained and knowledgeable on how to give a subcutaneous injection.
The main active ingredient in Depo-SubQ Provera 104 is Medroxyprogesterone acetate 104 mg.
The risks are low, but some women experience side effects when using Depo-SubQ Provera 104. Minor ones include (spotting) or some gain weight. Positive side effects are also a possibility, too — lighter bleeds are fairly common.
The chances of serious side effects from birth control pills are extremely unlikely, but some cases have been documented, such as unexplained vaginal bleeding, severe pelvic pain, severe abdominal pain, and bone pain. Depo-SubQ 104 has been associated with lower bone mineral density (BMD). However, pregnancy results in a greater potential loss of BMD. This method is not recommended for younger patients who have not yet reached their peak bone mass or patients with osteoporosis. Alternatives to Depo-SubQ Provera would be the pill, patch, ring.
If you experience swelling/itching of your face/throat/tongue, trouble breathing, or severe dizziness, this may indicate an allergic reaction, please call 911 or get to the emergency room to receive appropriate emergency medical treatment.
Do NOT take this medication if:
Do not have an IUD or have prolonged use of any type of sexual intercourse. This medication can cause decreased sexual desire and/or arousal,3. It is not recommended for use in women or children under the age of 18.Do NOT use this medication if:
Do NOT have a uterus or have had a history of endometriosis, ovarian failure, blood clots, blood disorders such as hemophilia, uteron.This does not mean a woman will experience a significant risk from men taking hormonal contraceptives. Women who are planning pregnancy must not take this medication.rollment is not usually problem. It is recommended to discuss other treatment options with your physician to ensure this medication is right for you.
This does not mean that all women who take this medication are safe to use. Women who have IUD implantation or need to be on progesterone for 12 weeks or more are more likely to be candidates for this medication.3. Women who are pregnant or who breastfeeding should not take this medication should not take this medication should use nonsteroidal anti-inflammatory drugs (NSAIDs) including oral ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn), or aspirin to prevent stomach upset. If pregnant or nursing, this medication should be used only when clearly needed during the first 10 days after implantation. If not, this medication may be more appropriate for later periods.
Abecheq is a prescription drug program that provides free prescription counseling to women experiencing serious or life-threatening health risks. With the help of an experienced provider, many women are able to live a more normal and happy pregnancy.
Read More This medication may have side effects such as3. Potential side effects include3.Do, especially the lighter the day, especially the lightest one (spotting), arearfused to cause decreased sexual desire and/or arousal.Spotting may be more likely if you have IUDs, endometriosis, or your periods have been irregular.3.
Depo-provera (medroxyprogesterone acetate) is an effective form of hormonal contraception that prevents ovulation and thrombosis in women at risk of this disease. Contraception can be administered through an intrauterine device or intramuscular injection, and a pregnancy test should be performed at the onset of the pregnancy. The use of Depo-provera should be considered for women at high risk of complications, and for those who have a history of thrombosis or endometrial cancer. The use of Depo-provera should also be avoided in patients with a history of ovarian hyperstimulation syndrome (OHSS) or other pelvic disorders related to the contraceptive method. In addition, women who are at risk of endometrial cancer should not use Depo-provera and should undergo a pelvic examination and/or pelvic ultrasound to exclude the possibility of ovarian hyperstimulation syndrome (OHSS).
In recent years, the Depo-provera contraceptive has been widely applied in the treatment of women at high risk of endometrial cancer. Many women have reported a decrease in the chance of endometrial cancer during Depo-provera use and this has been observed in men and women. This article will review the literature and the available data on the effectiveness of Depo-provera in the treatment of women at risk of endometrial cancer.
In the United States, Depo-provera has been the preferred contraceptive method for at-risk women because of its widespread use among young women and a proven effectiveness. Many studies have shown that Depo-provera has an effect on the incidence of endometrial cancer in women who use Depo-provera. However, it is important to note that there is limited information on the effects of Depo-provera on endometrial cancer. The Depo-provera contraceptive is effective for at-risk women who do not have other health issues such as endometriosis, but do have a history of endometriosis and endometrial hyperplasia. In addition, Depo-provera has a low risk of ovarian hyperstimulation syndrome (OHSS), and has been shown to prevent meningiomas in women who have had an endometrial lesion (pcos). It is also important to note that this contraceptive should be used by women who are not undergoing endometriosis treatment and for those who are at risk of endometrial cancer.
The use of Depo-provera should be considered for women at high risk of endometrial cancer, and for those who have a history of endometriosis and endometrial hyperplasia. In addition, women who are at high risk of endometrial hyperstimulation syndrome (OHSS) should undergo a pelvic examination and/or pelvic ultrasound to exclude the possibility of ovarian hyperstimulation syndrome (OHSS).
A review of the literature and epidemiology of endometrial cancer in women at risk of endometrial hyperstimulation syndrome (OHSS) found that women who use Depo-provera for at-risk women were at an increased risk of endometrial cancer compared with women who used only progestin-only contraception (seeDepo-Provera Contraceptive). The Depo-provera contraceptive should be used only in women at high risk of endometrial cancer.
The literature search included the following databases:
The PubMed database (for reviews and case reports).
The Cochrane Library database (for systematic reviews and meta-analyses).
A systematic review was carried out by the PRISMA® guidelines (for meta-analyses).
The following search terms were used:medroxyprogesterone acetate,depo-proveraand.
nervous system disorder
Depo-Provera Medroxyprogesterone Acetate is used in the treatment of women who have or have had (menstruation) or (prostate) cancer. It is also used to prevent the recurrence of (menstrual) cancer in women who have had cancer.
Depo-Provera Medroxyprogesterone Acetate is also used to prevent the recurrence of (menlammatory) cancer in women who have had cancer.
Depo-Provera is manufactured byCentre Genitourinary Medicine Ltd
Depo-Provera is available as 10 mg/ml oral suspension.
The dosage of Depo-Provera may vary depending on the patient’s age, body weight, and the need for progestational care. The recommended dose is one 5 mg injection every 12 weeks. The maximum recommended dosing frequency is once per day. The dosage of Depo-Provera may be administered by a doctor in the hospital, or patients can be given by an injection by a doctor. The medicine should be given by the doctor or nurse in the hospital, depending on the need for the medicine. It is important to follow the dosage instructions provided by the doctor or nurse. If the patient vomits the medicine, it is best to administer the rest of the medicine, even if the patient is feeling better. However, remember that the amount of medicine that needs to be given varies from patient to patient. If the patient experiences vomiting, the medicine should be given by the doctor or nurse and administered by the doctor. In some cases, the doctor may prescribe Depo-Provera for other patients who do not have symptoms, such as breast enlargement. In this case, the doctor may adjust the dose or recommend another progestational method.
Do not use Depo-Provera if you:
The most commonly observed adverse effects of Depo-Provera are:
If you experience any serious side effects such as severe skin reactions, fainting, or loss of appetite, inform your doctor immediately. The symptoms of a serious skin reaction may include:
Depo-Provera should not be given to patients who are pregnant or have any other known or suspected pregnancy. It is important to inform your doctor if you are breast feeding, and to follow all the instructions for taking the medicine, including the dose and duration of treatment, about the time and for how long. If you become pregnant while using Depo-Provera, inform your doctor immediately. If you are a woman of childbearing age, you should not use Depo-Provera. Depo-Provera should not be used in women who have or have ever had breast cancer.
Keep the medication out of the reach and sight of children. In case of unused Depo-Provera, return the medication to the pharmacy at once and discard the unused product. Do not use Depo-Provera if you are under the age of 18. It is important to tell your doctor if you are pregnant or breastfeeding.
ReferencesPfizer Inc. (Nasdaq: PFE), “Depo-Provera”, July 27, 2012. Accessed July 3, 2012..Reprinted withamins-to-breast-cancer-hormone-suppressing-pill-and-medications-pill
Cite Version 4.
Stade de France Pharmacy